Nyrada
ASX:NYRSydney, Australia· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileOverview
Australian‑listed biotech advancing TRPC‑channel inhibitors for cardiovascular and neurological unmet needs.
CardiovascularNeurologicalInflammationPainAutoimmune
Technology Platform
Proprietary TRPC ion‑channel inhibition using a benzopyran molecular scaffold to modulate cardiovascular, neuroprotective, and inflammatory pathways.
Opportunities
First‑in‑class TRPC inhibition offers a differentiated approach to cardioprotection and neuroprotection, with potential expansion into lipid‑lowering, pain and autoimmune markets.
Risk Factors
Clinical development risk for Xolatryp, reliance on external financing, and limited operating history increase uncertainty.
Competitive Landscape
Few companies target TRPC channels directly, giving Nyrada a unique niche, but broader competition from established cardioprotective and neuroprotective agents remains intense.